Clinical trials have advanced dramatically in precision, yet a large portion of chronic disease activity still occurs outside the clinic and outside traditional measurement windows. Nighttime symptoms, sleep‑related biomarkers and overnight deterioration are central to many conditions, but remain challenging to capture with diaries, morning recall or short‑duration assessments.

In this International Clinical Trials article, Albus Health CEO Mikesh Udani examines how continuous, passive monitoring is beginning to change that. He describes the longstanding gap between when disease manifests and when trials typically measure it — and how contactless technologies are now making it possible to capture objective nighttime physiology at scale, without adding burden to patients or sites.

The piece explores the evidence behind these approaches, including validation against clinical reference standards, long‑term usability data, and applications across asthma, COPD, heart failure, neurological conditions and safety monitoring. It also outlines the implications for trial design, from more sensitive endpoints to earlier detection of deterioration.

As continuous monitoring moves from exploratory pilots into protocol planning, it is reshaping how the industry understands treatment response, risk and disease biology, particularly in the domains that matter most to patients.

Read the full article here.